Alterations in Coagulation Factor Levels in Patients With End Stage Liver Disease

Launched by STANFORD UNIVERSITY · Aug 23, 2023

Keywords

ClinConnect Summary

This clinical trial is looking to better understand how certain blood proteins, called coagulation factors VIII and IX, change in patients who are going through liver transplantation due to severe liver disease. The main goal is to find out if the current guidelines for providing these factors to patients with bleeding disorders, like hemophilia, should be adjusted when they also have end-stage liver disease. This research could help improve treatment for these patients in the future.

To participate in the study, individuals need to be over 18 years old and have serious liver disease that makes them eligible for a liver transplant. They must also have a specific score, called MELD, which measures how badly their liver is functioning. Participants will be asked to provide two blood samples: one when they begin their liver transplant process and another after the transplant is completed. It's important to note that people who are having other organs transplanted at the same time or those with certain blood conditions or on specific medications cannot participate. This study is still in the planning stages and has not started recruiting participants yet.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • participants who have end stage liver disease who are listed for liver transplantation and have an accepted organ offer
• • age \> 18+
• • MELD \> 25
• Exclusion Criteria:
• • undergoing multi-organ transplant
• • tumor MELD exception points
• • has hereditary coagulation disease
• • currently on therapeutic blood thinner or anti-platelet medication (ie. aspirin, plavix, warfarin, heparin)